Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01467479 · ClinicalTrials.gov registry record · Phase 3
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
A Phase 3 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Terminated
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
NCT01467479 is a Phase 3 study that was terminated before completion, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 185 participants.
The verdict
NCT01467479, a Phase 3 study, was terminated before completion, sponsored by Vertex Pharmaceuticals Incorporated.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
Study Summary
The purpose of this study is to treat human immunodeficiency virus (HIV) and Hepatitis C Virus (HCV) co-infected subjects with telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) to achieve undetectable hepatitis C virus ribonucleic acid (HCV RNA) 12 weeks after the last planned dose of study drug.
Interventions
- DRUG Ribavirin
- DRUG Telaprevir
- DRUG Highly Active Antiretroviral Therapy (HAART)
- BIOLOGICAL Pegylated Interferon Alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01467479
The ClinicalTrials.gov registry entry for NCT01467479 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ribavirin is the first listed.
NCT01467479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01467479 about?
NCT01467479 is a clinical study titled "A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)". The purpose of this study is to treat human immunodeficiency virus (HIV) and Hepatitis C Virus (HCV) co-infected subjects with telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) to achieve undetectable hepatitis C virus ribonucleic acid (HCV RNA) 12 weeks after the last ...
What is the current status of trial NCT01467479?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2011-12. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01467479?
The interventions under investigation include: Ribavirin (DRUG), Telaprevir (DRUG), Highly Active Antiretroviral Therapy (HAART) (DRUG), Pegylated Interferon Alfa-2a (BIOLOGICAL).
Who is sponsoring clinical trial NCT01467479?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.